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Summary
Objective: Knee pain relief has been suggested to potentially alter radioanatomic positioning in conventional standing antero-posterior knee
radiographs. This study was performed to determine whether this is always the case and in particular if it applied to two recent randomised,
placebo-controlled trials showing both symptom- and structure-modiﬁcation with glucosamine sulfate in knee osteoarthritis.
Design: Patients in the two studies were selected if they completed the 3-year evaluations and, irrespectively of treatment, (1) were pain-im-
provers in that they underwent Western Ontario and McMaster Universities (WOMAC) osteoarthritis index (WOMAC) pain decrease at least
equal to the mean improvement observed with glucosamine sulfate, or (2) if their baseline standing knee pain (item #5 of the WOMAC pain
scale) was ‘‘severe’’ or ‘‘extreme’’ and improved by any degree at the end of the trials. Changes in minimum joint space width were then com-
pared between treatments.
Results: Knee pain was of mild-to-moderate severity in the two original studies and in all patient subsets identiﬁed here. Obviously, there were
more pain-improvers in the glucosamine sulfate than in the placebo subsets (N¼ 76 vs 57 in pooling the two studies), but WOMAC pain
scores improved to the same extent (over 50% relative to baseline). Notwithstanding such a major pain relief, patients in the placebo subsets
of both studies suffered a deﬁnite mean (SE) joint space narrowing, that was of 0.22 (0.15) mm in the pooled analysis, and that was not
observed with glucosamine sulfate: þ0.15 (0.07) mm; P¼ 0.003. Similar evidence was found in the smaller subsets with at least severe base-
line standing knee pain improving after 3 years.
Conclusions: Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials, pos-
sibly due to the mild-to-moderate patient characteristics. Consensus deliverables should acknowledge that the potential limitations of conven-
tional standing antero-posterior radiographs should not be overestimated since they may not apply to all patient populations and to all studies
using this gold standard technique.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Assessment of changes in joint space width by plain radiog-
raphy is the best available surrogate marker of articular car-
tilage loss and it is therefore the primary outcome measure
for the efﬁcacy of possible Disease Modifying Drugs, as rec-
ommended by scientiﬁc organisations and regulatory agen-
cies1e4. At the level of the knee joint, and in particular of the
femorotibial compartment, the gold standard radiographic
protocol is the standing antero-posterior fully extended
knee view, as reported in the Osteoarthritis Research
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2006.A1Society guidelines published in 19965. However, investiga-
tions have recently suggested potential problems of this
gold standard technique, mainly concerning standardisation
of the knee radioanatomic position6e8. While none of the re-
cent semi-ﬂexed views proposed to overcome some of the
theoretical limitations of conventional standing antero-pos-
terior ﬁlms has been sufﬁciently validated in longitudinal
studies so far9, as also conﬁrmed during this Workshop,
several studies have been in the meantime reported that
used the gold standard radiographic protocol and signiﬁ-
cantly increased our knowledge about the progression
of osteoarthritis in general and of joint structure changes
in particular10e13. In this regard, we have very recently
reported two prospective, 3-year, randomised, placebo-
controlled clinical trials that suggested, for the ﬁrst time
with any therapeutic intervention, the effect of glucosamine
sulfate as a Disease Modifying agent in osteoarthritis14,15.4
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conventional standing radiographic view. Indeed, the two
trials independently observed that glucosamine sulfate
was able to signiﬁcantly prevent the joint space narrowing
occurring in the patients receiving placebo throughout the
3 years of treatment. Interestingly, this ﬁnding has been
criticised9,16 for the potential confounding factor that might
have been introduced by the other major effect detected17,
i.e., the signiﬁcant improvement of symptoms in the glucos-
amine sulfate-treated patients compared with placebo. It
has been in fact hypothesised that the concomitant reduc-
tion in joint pain seen in the glucosamine sulfate arm rela-
tive to placebo may have altered the positioning of the
knee (in particular favouring a better knee full extension),
resulting in a change in joint space width that might have
confounded the estimate of joint space narrowing and exag-
gerated the differences between treatment groups9,16, as
suggested by recent experimental studies conducted on pa-
tients different than those in the glucosamine sulfate trials18.
For the purpose of this ConsensusWorkshop, the conven-
tional standing antero-posterior protocol has not been further
evaluated, in view of its potential limitations especially inmul-
ticenter studies (where standardisation may be a problem).
However, such limitations have probably been overesti-
mated9,16,18 relative to the validity of previous studies and
in particular of the glucosamine sulfate long-term trials.
The present re-analysis of our data in these two trials14,15
has been therefore undertaken in light of the recent criticisms
and in order to ﬁnally assess whether improvement in knee
painwas really a confounder in the assessment of joint space
width in our study populations and whether it biased the
structure-modifying effect reported for glucosamine sulfate.
Methods
The general methodology of the trials and patient inclu-
sions/exclusions are described in detail in the two original
study reports14,15. In brief, patients with knee osteoarthritis19
were randomly assigned to receive a 3-year continuous treat-
ment with either placebo, or crystalline glucosamine sulfate
(Dona, Viartril-S, Xicil, or other trademarks by the Rotta Re-
search/Rottapharm Group, Monza, Italy) at the oral dose of
1500 mg once-a-day as a soluble powder formulation, in
a double-blind fashion.
Radiographs were obtained at baseline and at yearly in-
tervals according to the gold standard standing (weight-
bearing) antero-posterior fully extended knee view. The
radiographic protocols were remarkably similar in the two
studies14,15. In particular, the focus to ﬁlm distance was
ﬁxed, as well as all other radiographic parameters and set-
tings. In addition, the posterior aspect of the knee was in
contact with the X-ray cassette to avoid variation in the dis-
tance between the knee and the cassette throughout the
study. Finally, ﬂuoroscopy was used to direct the X-ray
beam to the centre of the joint space, to control for joint ro-
tation and to maintain the same degree of alignment with
the tibial plateau in subsequent radiographs. In both trials,
patient repositioning was guided by the baseline ﬁlm and
aided by foot maps in the Reginster’s study and by placing
the feet together in the Pavelka’s study.
Joint space width of the medial femorotibial compartment
was assessed at the joint narrowest point by ‘‘chondr-
ometry’’20. Among symptom assessment measures, the
Western Ontario and McMaster Universities (WOMAC)
osteoarthritis index21 was used throughout the studies.
The visual analogue scale (VAS) version of the index(VA-3.0) was used in one trial14 and the Likert scale version
(LK-3.0) in the other15: changes relative to baseline are
therefore reported here as % changes, for uniformity reasons.
The aim of the present re-analysis was to assess whether
improvement in knee pain in the glucosamine sulfate arms
of the studies resulted in an artifactual increase in joint
space width, possibly by improving the ability of knee full
extension. Two different approaches were adopted to as-
sess this hypothesis.
In the ﬁrst approach, patients completing the 3-year treat-
ment course and the study evaluations were selected on
the basis of a major global knee pain improvement at the
end of the trial relative to baseline values, regardless of
treatment with glucosamine sulfate or placebo (i.e., both
drug and placebo responders). The cut-off of pain improve-
ment was set to a decrease in the WOMAC pain subscale
equal to the mean intention-to-treat improvement observed
in the glucosamine sulfate groups in the two original
trials14,15. Changes in joint space width in this subset of
pain-improvers were then compared by analysis of variance
to see if there was still any difference between the glucos-
amine sulfate and placebo groups: the working hypothesis
was that if major pain relief leads to artifactual increase in
joint space width, no joint space narrowing should be de-
tected in either of these patient subgroups, irrespectively
of treatment with glucosamine sulfate or placebo.
In the second approach, 3-year completers were selected
if they had a higher chance not to be able to fully extend
their knee at baseline due to severe pain while standing,
and if this pain had improved by any degree at the end of
the trials, again regardless of treatment. For this purpose
we used the ‘‘ﬂaring knee’’ deﬁnition described by Mazzuca
et al.18, and selected patients if they had reported at base-
line that standing knee pain (i.e., item #5 of the WOMAC
pain subscale) was ‘‘severe’’ or ‘‘extreme’’, i.e., score 3 or
4 on the 0e4 WOMAC Likert scale adopted in the study
by Pavelka et al.15 or, by analogy, >60 mm out of 100 in
the WOMAC VAS scale used by Reginster et al.14 In addi-
tion, for patients to be selected for this subset analysis, this
standing pain should have improved by at least 1 point on
the Likert scale, or >20 mm on the VAS scale. Changes
in joint space width were then again compared between
treatment groups by analysis of variance.
Results
A total of 212 and 202 patients (414 overall) were enrolled
in the two studies, respectively, and their characteristics have
already been described14,15. Patients had knee osteoarthritis
of mild-to-moderate severity, both from the point of view of
symptoms and in terms of baseline joint space.
There were obviously more patients (76 vs 57 in the two
studies combined) in the glucosamine sulfate pain-improver
subsets (drug responders) than in the placebo subsets (pla-
cebo responders) according to our ﬁrst approach, but the
mean (SE) baseline WOMAC pain scores were similar be-
tween treatments and only slightly higher compared to the
two original full study populations, but still in the mild-
to-moderate severity range: 228 (16) and 236 (18) sum of
VAS scores (mm) in the subsets from the Reginster’s study,
or 7.3 (0.4) and 8.0 (0.6) points in the Pavelka’s subsets, in
the glucosamine sulfate and placebo groups, respectively.
Joint space width in these pain-improver subsets was also
similar to that of the respective full study populations: 3.90
(0.15) mm in the glucosamine sulfate pooled subset and
3.94 (0.17) mm in the placebo subset.
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current re-analysis had a major decrease in 3-year WOMAC
pain scores irrespectively of treatment and in both studies,
that was 57.2 (3.1)% with glucosamine sulfate and 50.9
(3.1)% with placebo (NS) in the two studies pooled. Despite
major pain relief in both treatment subsets, of similar mag-
nitude between them, Fig. 1 shows that placebo-treated pa-
tients underwent an evident joint space narrowing that was
not detected in the patients who had received glucosamine
sulfate for the 3 years of the trials. Interestingly, the mean
degree of joint space narrowing attained with placebo in
these pain-responder subsets [Fig. 1(panels B and C)] after
3 years was in the same range of the changes observed in
the two original studies, similarly to the changes observed
in the glucosamine sulfate subsets14,15. By analogy, this
means that patients who did not improve their knee pain
or that did not reach the stipulated cut-off for pain relief
behaved in the same way (data not shown).
When we considered only patients with severe or ex-
treme standing knee pain at baseline and improving by
any degree after 3 years, the sample size was further re-
duced in these subpopulations, that consisted of only
12e15% of the total number of patients randomised in
each treatment group in the two original studies. Baseline
global WOMAC pain scores were still in the same mild-to-
moderate range and minimum joint space width baseline
values did not differ from those previously described as
well. Notwithstanding improvement in severe or extreme
standing knee pain, also in this case patients receiving pla-
cebo nevertheless experienced a deﬁnite joint space nar-
rowing that was not seen in those treated with
glucosamine sulfate (Fig. 2).
Discussion
Re-analysis of our data from two randomised, placebo-con-
trolled, double-blind, 3-year trials showingdisease-modiﬁcationwith glucosamine sulfate14,15 has clearly shown that the
structure-modifying effect of the drug, detected by conven-
tional standing antero-posterior knee radiographs, was not
biased by the concomitant pain relief induced by glucosamine
sulfate relative to placebo. This ﬁnding is contrary to what was
unduly postulated by recent reviews9,16 that suspected that
pain relief might have selectively improved knee extension
with a consequent alteration in radioanatomic positioning,
jeopardising the chance of seeing a joint space narrowing
with glucosamine sulfate. Indeed, our data demonstrate, with
two independent methodological approaches, that patients
experiencing major knee pain relief irrespectively of treatment
(i.e., drug responders or placebo responders), nevertheless
underwent joint space narrowing on placebo, but not when
they have been treated with glucosamine sulfate over the 3
years of the trials.
Conventional standing antero-posterior radiographs have
been recently criticised for their poor ability to prevent longi-
tudinal changes in medial tibial plateau alignment8,
although none of the new nonﬂuoroscopic semi-ﬂexed pro-
tocols has been shown to be deﬁnitely better in this re-
gard7,8 (and preliminary data presented during this
Workshop indicated that indeed only semi-ﬂexed antero-
posterior ﬂuoroscopically-assisted protocols may assure
satisfactory alignment). Actually, changes in alignment
may derive from failure to reproduce the degree of knee ex-
tension achieved at baseline, so that changes in the knee
extension/ﬂexion pattern may alter the distance between
the centre of the joint and the X-ray cassette. Several tech-
nical measures and positioning guidelines had been adop-
ted in the studies by Reginster et al.14 and by Pavelka
et al.15 to avoid this possibility and included the use of ﬂuo-
roscopy, that minimised the effect of medial tibial plateau
alignment and assured reproducibility of the radiographs
serially taken during the two trials22. In addition, the patients
enrolled in the trials had baseline disease in general, and
global knee pain levels in particular, of mild-to-moderate se-
verity and thus not preventing knee full extension on theA)  Both studies pooled  (N=57, 76)
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Fig. 1. Mean (SE) change in joint space width after 3 years in the global knee pain-improver subsets. Panel A reports the data pooled from
both studies, while panels B and C show the data from the single studies of Reginster et al. and of Pavelka et al., respectively. N stands for the
number of patients that qualiﬁed for the analysis in the placebo and glucosamine sulfate groups, respectively.
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Fig. 2. Mean (SE) change in joint space width after 3 years in the subset of patients with standing knee pain (item #5 in WOMAC pain scale) at
least severe at baseline and improving by any degree after 3 years. Panel A reports the data pooled from both studies, while panels B and C
show the data from the single studies of Reginster et al. and of Pavelka et al., respectively. N stands for the number of patients that qualiﬁed
for the analysis in the placebo and glucosamine sulfate groups, respectively.entry radiograph. The results of the present re-analysis are
therefore not in contrast with those of Mazzuca et al.18. In
fact, they showed that in patients with extreme severity
knee pain, joint space width artifactually increased with
pain relief18, but such severe patients are inadequate for
long-term, placebo-controlled Disease Modifying Drug trials
and, deﬁnitely, they did not enter the Reginster’s or the
Pavelka’s trial14,15. In fact, even when in the present re-
analysis we selected patients with extreme standing knee
pain at enrolment, their global WOMAC pain score was in
any case in the mild-to-moderate severity range. This was
therefore far from the extreme global knee pain severity
that can be deducted from the small sample in the study
by Mazzuca et al.18. A bias in patient repositioning
may therefore be operative only in patients with extreme
severity global knee pain scores and not in those with
mild-to-moderate severity enrolled in our long-term trials,
that rather seem to be more similar to those indicated by
Mazzuca et al. as ‘‘nonﬂaring’’ and in which pain relief did
not bias the assessment of joint space width18.
The changes in joint space width we detected in the sub-
sets of patients with major pain relief are similar to those re-
ported for the global patient populations of the two original
studies14,15, as well as to those of the opposite subset of
patients in which pain was not relieved to the same extent
or worsened. This conﬁrms that changes in knee pain did
not affect radiographic joint space narrowing assessment
in either way and that glucosamine sulfate protective effects
on joint structure changes were independent of the drug
symptomatic effect.
The conventional standing antero-posterior radiographic
protocol may have other inherent limitations in the assess-
ment of joint space width, including accuracy errors in mea-
surement due to parallax and to transmission of body
weight to a region of the joint which is not involved in normal
locomotion6,7. However, none of these can affect the differ-
ence in joint space narrowing we have observed betweenglucosamine sulfate and placebo that can be only attributed
to a difference in the loss of articular cartilage between
treatments. Sensitivity to change in joint space width and
precision errors are also issues that have been raised23,
whose improvement may favour detection of a difference
between placebo and an active drug with a smaller sample
size. However, they were not major problems in the two glu-
cosamine sulfate trials, since the drug was able to prevent
the natural (placebo) rate in joint space narrowing assessed
by the radiographic technique adopted and the sample size
calculated a priori proved to be large enough to detect a sig-
niﬁcant difference between treatments in both independent
studies14,15. In addition, we have now conﬁrmed a similar
joint space narrowing rate, with a similar precision, irrespec-
tively of knee pain behaviour.
In conclusion, major relief in mild-to-moderate global
knee pain is not a confounder in the evaluation of joint
space narrowing on standing antero-posterior knee radio-
graphs taken in full extension. Misleading information9,16,18
has been released in this regard relative to the validity of the
structure-modifying effects of glucosamine sulfate in two re-
cent independent long-term trials14,15. Conversely, these
structure-modiﬁcation results are valid and were not biased
by the concomitant symptom-modiﬁcation observed with
the drug, nor by any other limitations in the conventional
radiographic technique adopted.
While acknowledging the inherent limitations of conven-
tional standing antero-posterior radiographic protocols,
that may suggest adoption of more efﬁcient techniques in
the future, care should be taken in verifying whether real
biases occurred in previous studies using such gold stan-
dard, prior to raising unjustiﬁed warnings. Consensus deliv-
erables from this Workshop should acknowledge these data
and rectify previous misleading information released on the
extent of the limitations of conventional standing antero-
posterior radiographs and on the validity of the glucosamine
sulfate long-term trials.
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